IDEAYA Biosciences (IDYA) Non Operating Income (2019 - 2026)
IDEAYA Biosciences (IDYA) posted Non Operating Income of $10.0 million for Q1 2026, down 11.44% sequentially from $11.3 million in Q4 2025, and down 18.07% YoY from $12.2 million in Q1 2025.
IDEAYA Biosciences (IDYA) Non Operating Income (2019 - 2026) Analysis & Trends
IDEAYA Biosciences has reported Non Operating Income for 8 years, with the latest figure at $10.0 million in Q1 2026.
- Quarterly Non Operating Income fell 18.07% year-over-year to $10.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $43.4 million (down 18.5% YoY) and the FY2025 annual result came in at $45.6 million, down 13.11% from the prior year.
- Non Operating Income declined to $10.0 million in Q1 2026 per IDYA's latest filing, from $11.3 million in the prior quarter.
- Over five years, Non Operating Income peaked at $15.1 million in Q3 2024 and troughed at $207000.0 in Q1 2022.
- A 5-year average of $7.8 million and a median of $10.0 million in 2026 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2022 and 2025: Non Operating Income jumped 1328.03% in 2022, then decreased 28.4% in 2025.
- Over 5 years, Non Operating Income stood at $2.2 million in 2022, then surged by 255.13% to $8.0 million in 2023, then surged by 73.65% to $13.8 million in 2024, then declined by 18.29% to $11.3 million in 2025, then fell by 11.44% to $10.0 million in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered $10.0 million, $11.3 million, and $10.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | IDEAYA Biosciences | 3.50 Bn | 2.67 Bn | - | 9.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.84 Mn |
| Mar 31, 2026 | 10.01 Mn |
| Dec 31, 2025 | 11.30 Mn |
| Sep 30, 2025 | 10.79 Mn |
| Jun 30, 2025 | 11.32 Mn |
| Mar 31, 2025 | 12.21 Mn |
| Dec 31, 2024 | 13.83 Mn |
| Sep 30, 2024 | 15.07 Mn |
| Jun 30, 2024 | 12.16 Mn |
| Mar 31, 2024 | 11.45 Mn |
| Dec 31, 2023 | 7.96 Mn |
| Sep 30, 2023 | 6.09 Mn |
| Jun 30, 2023 | 4.78 Mn |
| Mar 31, 2023 | 2.64 Mn |
| Dec 31, 2022 | 2.24 Mn |
| Sep 30, 2022 | 955,000.00 |
| Jun 30, 2022 | 443,000.00 |
| Mar 31, 2022 | 207,000.00 |
| Dec 31, 2021 | 157,000.00 |
| Sep 30, 2021 | 131,000.00 |